1. Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer. Issue 1 (21st September 2022) Authors: Taniguchi, Hirokazu; Akagi, Kazumasa; Dotsu, Yosuke; Yamada, Tadaaki; Ono, Sawana; Imamura, Erika; Gyotoku, Hiroshi; Takemoto, Shinnosuke; Yamaguchi, Hiroyuki; Sen, Triparna; Yano, Seiji; Mukae, Hiroshi Journal: Cancer science Issue: Volume 114:Issue 1(2023) Page Start: 164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗